Hemodynamic Support Devices

This hemodynamic support systems include intra-aortic balloon pumps (IABP), percutaneous ventricular assist devices (pVAD) like the Impella or tandemheart, and ventricular assist devices (VAD).

FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019

June 12, 2019 — In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that...

Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019

May 22, 2019 — Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at...

SCAI Releases New Consensus Document on Classification Stages of Cardiogenic Shock

Image courtesy of the Society for Cardiovascular Angiography and Interventions (SCAI).

News | Cardiogenic Shock | May 20, 2019

May 20, 2019 – A newly released expert consensus statement proposes a classification schema for...

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019

May 14, 2019 — The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and...

FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019

May 2, 2019 — Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation...

The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.

The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.

Podcast | Hemodynamic Support Devices | May 02, 2019

This podcast is a discussion with ...

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.

The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms....

Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators

Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions...

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019

April 5, 2019 — Three years ago this week, Abiomed's Impella...

Illustration showing the venous implantation route and where the inlet and outflow ports are when the Abiomed Impella RP is placed in the right side of the heart. The  Impella RP catheter is used for right heart hemodynamic support.

Illustration showing the venous implantation route and where the inlet and outflow ports are when the Impella RP is placed in the right side of the heart. 

Feature | Hemodynamic Support Devices | March 26, 2019 | Perwaiz Meraj, M.D. FACC and Uma Chandrasekaran, Ph.D.

Right heart failure (RHF) is a syndrome characterized by the inability of the right ventricle (RV) to support...

HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019

March 22, 2019 — Severely ill patients with advanced...

The top five most important take-away presentations from the 2019 Society of Thoracic Surgeons (STS) annual meeting.
Blog | Cardiovascular Surgery | February 25, 2019

Here is what I thought were the top five most important take-away presentations from the 2019...

Two devices where safety is being called into question based on clinical data that is being questioned. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Blog | Cath Lab | February 20, 2019

Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...

Overlay Init